LEHI, UT / ACCESSWIRE / October 30, 2019 / Frelii, Inc. (OTC PINK:FRLI) (“Frelii” or “the Company”), a biotechnology company working to commercialize its patent-pending DNA gene sequencing artificial intelligence technology, announced today an update to shareholders regarding technology and marketing advancements.
Frelii’s CEO, Ian Jenkins stated, “Over the past year, through the diligence of our development team, led by respected industry leader Jayson Uffens, the Company has successfully navigated a variety of challenges, resulting in critical enhancements to our technology offering. In conjunction with our strategic marketing efforts to solidify numerous revenue verticals, we believe the Company is well positioned to execute a multifaceted growth strategy designed to build long-term shareholder value.”
The Company utilizes artificial intelligence and whole genome analysis to increase patient outcomes and reduce direct costs. In the last year, the Company has significantly reduced the amount of time required to analyze 3.2 billion DNA data points to under five minutes. The same analysis process previously required over 166 hours to complete.
This resulting refinement is expected to enable the Company to expedite the servicing of its diverse marketing channels and facilitate scalable growth earlier than had previously been expected.
The Company expects its partnership with Optivida Health and GATC Canna to solidify the technology offering’s two initial verticals:
– As a medical cannabis reference tool, working through physicians to effectively highlight risk factors, optimally match plant strains to each individual and provide the basis for accurate dosing recommendations; and
– As a general health & wellness tool, providing a multitude of product recommendations based specifically on the results of DNA analysis.
Additionally, the Company is evaluating strategies to expand its technology outside of the United States, initially in Canada, a jurisdiction that has legalized cannabis use across all provinces and territories. To that end, earlier this year the Company announced that it has incorporated a Canadian subsidiary, Frelii Canada Inc, and opened an office in Mississauga, Ontario, Canada.
“I want to personally thank our executive team and staff for their tremendous efforts, in addition to our loyal shareholders for their ongoing support”, Jenkins concluded, “This support has contributed greatly to the Company’s bright future, which we plan to be driven by a diverse stable of applications leveraging our patent-pending technology.”
About Frelii Inc.
Frelii Inc. is a biotechnology company utilizing human DNA gene sequencing and artificial intelligence (AI) to assess more than 3.2 billion markers on the human genome. The resulting data provides valuable insight into an individual’s DNA which are aligned and leveraged against its AI as a means of creating a robust data platform for use by a variety of sectors, including Health & Wellness, Healthcare, Medical Cannabis and Pharmaceutical.
For more information, please visit www.frelii.com or follow us online at:
Frelii Facebook Page https://www.facebook.com/livefrelii/
Frelii Twitter Feed @livefrelii
Frelii Instagram Page @livefrelii
Frelii LinkedIn Page linkedin.com/company/frelii/
For questions and inquiries please contact: Seth Jones, firstname.lastname@example.org
Safe Harbor Statement:
This release contains certain “forward-looking statements” relating to the business of the Company. All statements, other than statements of historical fact included herein are “forward-looking statements” including statements regarding: the continued growth of the e-commerce segment and the ability of the Company to continue its expansion into that segment; the ability of the Company to attract customers and partners and generate revenues; the ability of the Company to successfully execute its business plan; the business strategy, plans, and objectives of the Company; and any other statements of non-historical information. These forward-looking statements are often identified by the use of forward-looking terminology such as “believes,” “expects” or similar expressions and involve known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks, and uncertainties, and these expectations may prove to be incorrect. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this news release. The Company’s actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those discussed in the Company’s periodic reports that are filed with the Securities and Exchange Commission and available on its website (http://www.sec.gov). All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these factors. Other than as required under the securities laws, the Company does not assume any duty to update these forward-looking statements.
SOURCE: Frelii, Inc.
View source version on accesswire.com: